Trial Profile
A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Foscenvivint (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors PRISM Pharma Co
- 05 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015, as reported by ClinicalTrials.gov record.
- 05 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Planned End Date changed from 1 May 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.